Watch and Wait for Rectal Cancer: A Risky Gamble or a Safe Strategy for Patients With a Near-Complete Response? Co-authored by @fdossa. Read the full article. bit.ly/4vuPmU8

I was skeptical of virtual twin studies but @fdossa convinced me they have a role, especially for our patients with rare cancer. Look forward to seeing what’s next out of this line of research #ASCO26 #sarcoma 👇🏻

SARC041: confirms clinical activity of abemaciclib for pts with advanced dediff liposarcoma ✅ 👏🏽 to Mark Dickson @MSKSarcoma on this work and Paolo Casali @casali_pg @IstTumori for an excellent discussion Open❔role in resectable disease #ASCO26

A much needed breakthrough for our pts with #PDAC 👏👏. Glad to see amongst investigators for this important study, our fearless #GImedonc leader @DrHendifar as an author in the @NEJM manuscript @OncoAlert @DrArsenOsipov @AGangiMD @_BrainyMD_ @CFerroneMD @fdossa @CedarsSinaiMed

Congratulations to @DrDrFoster of @Stanford University, recipient of the SSAT Career Development Award! 🎉 Dr. Foster’s work reflects the innovation and dedication that continue to advance the field of digestive diseases. #Surgery #AcademicMedicine #Research #StanfordUniversity

This is a great read on watch & wait in rectal cancer. B/c patients with local regrowth after WW have higher rates of distant mets, there has been an intuitive fear that regrowth is causal (i.e delaying TME permits metastatic seeding hence WW risky). The authors here argue (and I agree) that regrowth/metastases are manifestations of intrinsic aggressive tumor biology because: 1) no difference in time to surgery in patients w pCR/regrowth who developed mets vs. those who didn't (if delay were causal, would expect longer delay in patients who developed M1). 2) in OPRA secondary analysis, patients with cCR underwent least surgery/longest observation while those with incomplete response had surgery most frequently/immediately. But outcomes still tracked with response phenotype not timing of surgery (i.e. cCR did best). 3) tumor response itself is prognostic (i.e. even when all pts undergo TME, more regression after neoadjuvant therapy --> better DFS/DM). 4) modern tumor evolution data suggest metastatic spread mostly happens early. 5) chemo/radioresistance appears to be linked to metastatic potential (i.e. regrowth is a marker of aggressive biology not the mechanism itself). IMO a persuasive argument against hypothesis that regrowth seeds metastasis, but rather biology=dominant driver. @OncoAlert

Thrilled to finally see this out - 🚨#Sarculator bayesian update for more refined risk estimates in extremity soft tissue sarcoma App📱update and @LancetOncology pub: sciencedirect.com/science/ar… Phenomenal work @DCalleMD, Gabriele Tine, et al. ! 👏🏽👏🏽

With ⤴️use of W&W for rectal cancer, how can we safely 🫸the limits? Is there a role for W&W in pts with *near* complete response or does this risk distant disease? More on the📊 and our recommendations for safe W&W practices: ascopubs.org/doi/10.1200/JCO… @JCO_ASCO @DrGarciaAguilar

New RCT data 📈 supporting the efficacy of Doxil for progressing desmoid tumors. Now 3 options supported by level 1 data - but how to choose? 🧐 👀 editorial in @CCR_AACR with @SilviaStacchia and @alegronchi aacrjournals.org/clincancerr…

Congrats @seacm! 👏🏽 👏🏽

Great way to cap off #colorectalcancer awareness month hosting our @CSCancerCenter #CRC research social w/Dr. Alessio Pigazzi @EdwinPosadasMD for a productive exchange of ideas, networking & future collabs w/PhDs & MDs in #CRC research @AGangiMD @fdossa @SGrivennikov @SekiEki

Building on terrific #SSO2026 and @TARPSWG meetings, check out our📄on current dx & tx strategies for soft tissue sarcoma @BjsOpen, including recent technical advances and multiD approaches @ctosociety @SocSurgOnc @ESSOnews @_CSSO @FioreDoc @alegronchi academic.oup.com/bjsopen/art…

ctDNA🩸: game-changer or expensive crystal ball?🔮 💡What surgeons should do with ctDNA in CRC, gastric & cholangiocarcinoma at #SSO2026 with @ColinCourtMD @fdossa @FlavioRochaMD & wrap-up by @rachnatshroff Join us in Phoenix👉🏻 tinyurl.com/55upkjsr

Sarcoma family dinner 💛thank you @SilviaStacchia and @alegronchi for welcoming us into your home, workplace and international sarcoma family! @TARPSWG @ctosociety @UofTSurgOnc

Thanks so much for the invite! Really enjoyed the discussion that followed about the future of #clinicaltrials in oncology - improving design and interpretation!

Kicking off #CTOS2024 with @TARPSWG this morning. @FioreDoc leading the discussion on 🌎 collaboration to standardize RPS terminology 👏👏 #CTOSTweeTOS

TOPGEAR: In a trial comparing chemotherapy and preoperative chemoradiotherapy with perioperative chemotherapy in patients with resectable gastric or GE junction cancer, no significant difference in overall survival was noted. Full trial results: nej.md/4gg4gqv #ESMO24

It’s out! This guideline @JAMAOnc #desmoid reflects our multidisciplinary global collaboration, highlights new treatment strategies &importance of quality of life. Thanks Bernd Kasper, @alegronchi, pts, all. Current Management of Desmoid Tumors: A Review. pubmed.ncbi.nlm.nih.gov/3890…

Congrats to the graduating fellows ⁦@MSKCancerCenter⁩!!! Huge honor to train alongside this crew - looking forward to our 2nd year! ⁦@MichaelDAngeli2⁩ @wei_ac ⁦@fdossa⁩ ⁦@SaadatLily⁩ ⁦@nelfarrow⁩ ⁦@JSJolissaint⁩ ⁦@Pllcg3⁩

Proud to share this major collaborative effort with everyone. I will share my thanks at the end of this thread. But first, I want to share some key points to take away from this paper on #cancer risk due to #CDH1...